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Abstract In this study, after conﬁrming the suppression of
autonomic nervous function by isoﬂurane anesthesia using
autonomic antagonists, we pharmacologically investigated
the involvement of vasomotor and cardiac sympathetic
functions in systolic blood pressure variability (SBPV) fre-
quency components in conscious rats at rest and during
exposuretolow-ambienttemperature(LT-exposure,9Cfor
90 min). Under unanesthesia, phentolamine administration
(a-adrenoceptor antagonist, 10 mg/kg) decreased the mid-
frequency component (MF 0.33–0.73 Hz) and inversely
increased the high-frequency component (HF 1.3–2.5 Hz).
The increased HF was suppressed by subsequent treatment
withatenolol(b-adrenoceptorantagonist,10 mg/kg),butnot
with atropine (muscarinic receptor antagonist, 10 mg/kg).
Moreover, phentolamine administration after atenolol
decreased MF, but did not increase HF. LT-exposure
increased MF and HF; however, phentolamine pretreatment
suppressed the increased MF during LT-exposure, and
atenolol pretreatment dose-dependently decreased the
increasedHF.TheseresultssuggestthatMFandHFofSBPV
may reﬂect a-adrenoceptor-mediated vasomotor function
and b-adrenoceptor-mediated cardiac sympathetic function,
respectively, in the conscious state.
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Introduction
Blood pressure (BP) and heart rate (HR) continuously
ﬂuctuate over time under the inﬂuence of control mecha-
nisms such as autonomic nerve activity, humoral factors
and respiration for maintaining cardiovascular homeostasis.
Among the methods used for analyzing these ﬂuctuations,
frequency domain analysis of cardiovascular variability has
been used most often as an index of autonomic circulatory
control [1]. In particular, heart rate variability (HRV) has
become an increasingly popular index for the assessment of
autonomic nervous system (ANS) characteristics such as
vagal function or cardiac sympatho-vagal balance [2, 3].
However, when evaluating cardiac sympathetic regulation,
HRV should be used with discretion since HRV merely
reﬂects the relative value of sympatho-vagal balance; fur-
thermore, the sympathetic and vagal functions are not
always reciprocal under all conditions [4]. Systematic and
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pathetic functions may be key to understanding complicated
pathological conditions because activity of the sympathetic
nervous system is regionally speciﬁc (heart, vessels, etc.).
However, no reliable and accessible tool exists for simul-
taneous evaluation of vasomotor and cardiac sympathetic
nervous function as separate measures.
Information regarding ANS provided by systolic arterial
blood pressure variability (SBPV) is different from that
provided by HRV. SBPV is commonly analyzed on the
basis of low-, mid- and high-frequency components (LF,
MF and HF, respectively) of the power spectrum. It has
been reported that LF may be mediated by sympathetic
and/or humoral factors including the renin-angiotensin
system [5], and MF may show strong coherence with
synchronous oscillations of post-ganglionic sympathetic
nerve activity [6–8] and be decreased by a-adrenoceptor
blocker [9–11]. It has been suggested that the genesis of
MF may involve in the sympathetic vasomotor component
of the arterial baroreceptor reﬂex; however, it is not known
exactly if MF is solely dependent on the a-adrenoceptor-
mediated sympathetic nervous system. Experiments under
various physical conditions including external stimuli are
thus necessary to make MF more applicable. The mecha-
nism underlying HF has not been adequately explained
despite several studies indicating that it is a mechanical
consequence of respiration [12, 13] and other studies sug-
gesting an association between HF and ANS, particularly
the b-adrenergic system [14–16]. To make progress in the
availability of SBPV frequency analysis for the evaluation
of sympathetic cardiovascular function, the association
between the sympathetic nervous system and SBPV must
be determined.
Most studies of the involvement of sympathetic car-
diovascular function in SBPV (particularly in respiratory
HF) are conducted under anesthesia [14–16]; therefore,
little is known concerning the natural responses to stimuli
under unanesthesia when ANS is not suppressed. It is
meaningful to examine the ANS response in a conscious
state in order to evaluate complicated pathological condi-
tions (e.g., chronic pain) in human [17] and animal models
[18–20].
We hypothesized that MF and HF in SBPV in the
conscious state may be involved in the a- and b-adrenergic
system, respectively. In the present study, to identify SBPV
characteristics, we focused on changes in ANS in a con-
scious state and explored the link between ANS function
and SBPV by means of sequential administration of auto-
nomic antagonists and sympathetic activation stimulus. We
ﬁrst identiﬁed differences in autonomic nervous function
between anesthetized and unanesthetized states using
autonomic antagonists. Then, to elucidate the involvement
of vasomotor and cardiac sympathetic functions in SBPV
frequency components in conscious rats, we investigated
responses to combined administration of autonomic
antagonists at rest and in a systemic sympathetic activated
state by exposure to low ambient temperature (LT-expo-
sure). A strong relationship between SBPV and a- and
b-adrenoceptor-mediated sympathetic function was revealed
in conscious rats. Exploration in the frequency domain of
cardiovascular regulation in animals could enhance our
understanding of the pathology of autonomic dysfunction
in humans. Our results suggest that SBPV may be used as a
tool for detailed assessment of vasomotor or cardiac sym-
pathetic functions.
Materials and methods
All experiments in this study were carried out according to
a protocol approved by the Animal Care Committee at the
Aichi Medical University and to the Fundamental Guide-
lines for Proper Conduct of Animal Experiments and
Related Activities in Academic Research Institutions in
Japan.
Materials
The experiments were performed using male Sprague-
Dawley rats (300–400 g, SLC Inc., Japan). The rats were
housed under controlled ambient conditions (23 ± 0.5C,
50 ± 10%) with a 12-12 h light/dark cycle and provided
food and water ad libitum. To minimize effects attributable
to circadian alterations, all experiments in this study were
conducted between 10 a.m. and 5 p.m. Recordings were
performed in a silent room under controlled ambient con-
ditions, as noted above.
Autonomic blockers
Phentolamine mesilate (10 mg/kg), a non-selective a-
adrenoceptor antagonist, was obtained from Novartis
Pharma (Tokyo, Japan). Atenolol (1 and 10 mg/kg), a
selective b1-adrenoceptor antagonist, and atropine methyl
bromide (10 mg/kg), a non-selective muscarinic receptor
antagonist, were purchased from Sigma (St. Louis, MO).
Each drug was dissolved in saline and injected intraperi-
toneally (i.p.). To examine the effects of drugs on periph-
eral ANS, we chose these drugs that do not cross the blood-
brain barrier. The concentration of each drug (10 mg/kg)
was determined in a pilot study: we ensured that each drug
provided a sufﬁcient effect over 60 min and gradual
recovery 2–3 h after injection.
During this research, we recorded BP continuously for
3 days just after our manipulation (administration of drug
or LT-exposure) and examined the effect of the
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after the manipulation, the BP ﬂuctuation pattern returned
to normal levels regardless of treatment type. Therefore,
we presume that pharmacological manipulation in this
study might not have affected the conscious state on the
following day of the experiment.
Data acquisition and analysis of cardiovascular
parameters
Telemetric monitoring of arterial blood pressure
and heart rate
A telemetry system (Primtech Ltd., Japan) was used to
continuously record arterial blood pressure (BP) in con-
scious rats. A radio transmitter equipped with a BP trans-
ducer (Physiotel TA11PA-C40, Data Science International,
USA) was implanted as follows: (1) under pentobarbital
anesthesia (50 mg/kg, i.p.), a catheter connected to the BP
transducer was introduced into the abdominal aorta just
below the renal artery, (2) the body of the transducer was
ﬁxed in the abdominal cavity, and (3) the incision was
closed with sutures after antibiotics were sprayed into the
abdominal cavity. Continuous recording of BP was initi-
ated at least 1 week after operation in unrestrained and
conscious rats.
Electrical signals transformed from BP of rats in each
cage were detected by the receiver of the telemetry system,
ampliﬁed using an electrical circuit in the receiver, and led
to a 12-bit A/D converter (PCI-6040E, National Instru-
ments, USA) that digitized the analog signals at a rate of
200 Hz. The converter was controlled by a personal com-
puter. The sampling procedure was programmed using
LabVIEW 7.1 (National Instruments). The executable
program was developed in our laboratory.
A maximum value corresponding to systolic arterial
blood pressure (SBP) and its generation time, which was
also utilized to calculate instantaneous heart rate (HR), for
each pulse wave of BP were detected, and time series of
SBP (TSSBP) and HR (TSHR) were constructed. Subse-
quently, to create a power spectrum with a frequency range
up to about 10 Hz by using a continuous wavelet trans-
form, TSSBP with irregular intervals was reconstructed with
a regular interval of 18.2 Hz, so-called resampling.
For this procedure, we used the ‘‘Smooth Spline’’
function in the software R (http://www.r-project.org/),
which is a freeware program used for statistics and signal
processing.
Frequency analysis of blood pressure ﬂuctuations
With resolutions of time and frequency of about 55 ms and
0.018 Hz, respectively, the power of each frequency at
each time point in the variability of TSSBP was calculated
using a continuous Gabor wavelet transform of TSSBP.
Three prominent peaks of power were frequently
observed on this SBPV spectrum in different frequency
bands, namely high-frequency (HF 1.3–2.5 Hz), mid-fre-
quency (MF 0.33–0.73 Hz) and low-frequency components
(LF 0.04–0.31 Hz). In this study, averaged power values
within each component over successive 5-min periods were
employed as instantaneous power values for each fre-
quency component at a given time point. On comparing
SBPV and the variability of diastolic BP, we found that the
power of LF and MF was similar in both variabilities, but
that of HF was more prominent in SBPV in our pilot study;
this result is consistent with that reported by other studies
[21, 22]. Therefore, we used the variability of TSSBP in this
study.
Experimental protocol
Experiment 1: Effects of isoﬂurane anesthesia
on cardiovascular parameters
Data were recorded in 5 rats in the anesthetized and
unanesthetized states. In the experiment conducted in the
unanesthetized state, a rat was kept singly in an acrylic
cage (W 300 mm, H 130 mm, D 205 mm). After recording
baseline data for 10 min during the stabilization period, we
administered atropine (10 mg/kg, n = 5) or phentolamine
(10 mg/kg, n = 5) intraperitoneally. We employed 10-min
data for 10–20 min after each injection.
Experiments in the anesthetized state were performed as
follows: (1) anesthesia was induced in the rats with 1.3%
isoﬂurane in oxygen and an oral tube was attached, (2) the
concentration of anesthesia was changed and maintained at
0.5–0.9% isoﬂurane in oxygen, (3) after recording 10-min
data as baseline (approximately 20 min after administra-
tion of 0.5–0.9% isoﬂurane anesthesia), we administered
atropine (10 mg/kg, n = 5) or phentolamine (10 mg/kg,
n = 5). The value after the administration was averaged
10-min data for 10–20 min after each administration.
SBPV was analyzed using the 10-min baseline data
recorded before administration in the anesthetized (n = 5)
and unanesthetized state (n = 5). SBP, HR and each
component of SBPV were computed from the BP wave, as
described above.
Experiment 2: Effects of autonomic blockers
on cardiovascular parameters in conscious rats at rest
A rat was kept singly in the same acrylic cage as that used
in Experiment 1. After recording baseline data for 20 min
during the stabilization period, we administered phentol-
amine (10 mg/kg, n = 10) or atenolol (10 mg/kg, n = 10)
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123intraperitoneally as a ﬁrst injection. A second injection was
done 35–40 min after the ﬁrst injection: atenolol (10 mg/
kg, n = 5) or atropine (10 mg/kg, n = 5) after phentol-
amine treatment; phentolamine (10 mg/kg, n = 5) or
atropine (10 mg/kg, n = 5) after atenolol treatment. We
then calculated and averaged the 20-min data determined
during the 10–30 min period after each injection.
Experiment 3: Effects of autonomic blockers
on cardiovascular parameters in conscious rats
during exposure to low ambient temperature (LT-exposure)
A rat was kept singly in the same acrylic cage as that used
in Experiment 1 placed inside a box made of polystyrene
foam (W 350 mm, H 210 mm, D 280 mm). After record-
ing baseline data for 30 min, crushed ice was placed in the
space between the cage and the box. The ambient tem-
perature in the cage fell to approximately 9C from 23Ci n
about 20 min and was maintained at approximately 9C for
70 min (total LT-exposure, 90 min). After LT-exposure,
the ice was removed, and the temperature returned to the
prior level in approximately 25–30 min. In the control
group, LT-exposure was performed as described above in
rats that were not administered an autonomic blocker
(n = 9). In the autonomic blocker groups, the rats were
administered phentolamine (10 mg/kg, i.p., n = 5), low-
dose atenolol (1 mg/kg, i.p., n = 5) or high-dose atenolol
(10 mg/kg, i.p., n = 5) 30 min before LT-exposure. In a
pilot study, we conﬁrmed that, when the ambient temper-
ature was changed (20, 15, 9, 7C), HR showed a tem-
perature-dependent increase and that there was no
signiﬁcant change in HR-increase at 9 and 7C. Therefore,
we presume that the LT-exposure we used (9C) may be
efﬁcient enough to induce high sympathetic activation.
Baseline cardiovascular parameters measured over
30 min before LT-exposure were averaged. We calculated
90-min data recorded throughout LT-exposure because the
gradual decrease in temperature induced an ANS response.
Statistical analysis
All data in Experiment 1 are presented as mean ± SEM.
SBP and HR in Experiments 2 and 3 are presented as box
(median ± interquartile range) and whisker (5 and 95
percentile values) plots, and data values for each SBPV
component are expressed as mean ± SEM. A paired t test
was employed to compare the data before and after drug
administration, data recorded in the anesthetized and
unanesthetized states in Experiment 1, before and after
administration of the ﬁrst drug in Experiment 2, and before
and during LT-exposure (control) in Experiment 3. Two-
way analysis of variance (ANOVA) and Holm’s post hoc
tests were utilized to compare treatments with drugs in
Experiment 2. To compare all LT-exposure groups in
Experiment 3, one-way ANOVA and Holm’s post hoc tests
were utilized. Differences were considered statistically
signiﬁcant at the p\0.05 level.
Results
This experiment revealed pharmacologically that MF and
HF components of systolic arterial blood pressure vari-
ability (SBPV) changed along with a- and b-adrenoceptor-
mediated sympathetic functions, respectively, in conscious
rats. Before describing these results, we ﬁrst report on the
effects of isoﬂurane anesthesia on ANS.
Effects of isoﬂurane anesthesia on autonomic nervous
function
In the anesthetized state, HR and SBP before administra-
tion of autonomic blockers were signiﬁcantly different
from those in the unanesthetized state; HR was markedly
higher and SBP was signiﬁcantly lower under anesthesia
(Fig. 1a, b; see baseline). Spectral analysis of SBP baseline
data showed that LF and MF components of SBPV under
anesthesia were signiﬁcantly lower than those under
unanesthesia (LF p = 0.0186, MF p = 0.0191) (Fig. 1c).
HF did not differ in the anesthetized and unanesthetized
states (Fig. 1c).
Changes in HR as a direct effect of atropine (10 mg/kg,
i.p.), which is a parasympathetic blocker to the heart, are
shown in Fig. 1a. In the unanesthetized state, atropine
administration increased HR (293.7–397.2 bpm,
p = 0.0002), as expected. In contrast, in the anesthetized
state, HR remained unchanged from the baseline level after
atropine administration; thus, it was signiﬁcantly lower
than that in the unanesthetized state. Under anesthesia, HR
did not show the direct effect of atropine. Atropine also
increased SBP (110.4–123.2 mmHg, p = 0.0159) under
unanesthesia, but had only an insigniﬁcant effect on SBP
under anesthesia (data not shown).
In the unanesthetized state, treatment with phentolamine
(10 mg/kg, i.p.) as an a-adrenoceptor-mediated sympathetic
blocker signiﬁcantly decreased SBP (113.9–81.3 mmHg,
p = 0.0099) and increased HR (286.3–399.4 bpm,
p = 0.0009), which is similar to the response of HR to
atropine (Fig. 1a, b). In contrast, in the anesthetized state,
phentolamine administration did not induce an increase in
HR, despite a signiﬁcant decrease in SBP (90.0–
72.7 mmHg, p = 0.0059) (Fig. 1b). Anesthesia induced
changes of baseline in SBP and HR, and also strongly
affected HR when the a-adrenoceptor blocker was treated.
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parameters in conscious rats at rest
Figure 2 displays typical changes in cardiovascular param-
eters with subsequent administration of atenolol (10 mg/kg,
i.p.) after phentolamine treatment (10 mg/kg, i.p.) in a con-
sciousrat(Experiment2).Phentolaminetreatmentdecreased
SBP and increased HR, as described in the results obtained
for the unanesthetized state in Fig. 1b. Intermsof frequency
components, MF decreased and LF slightly declined,
whereas HF was considerably increased by phentolamine
administration.Thesechangeswerekeptstablefrom10 min
after the administration. Atenolol administration after
phentolamine treatment induced sharp and signiﬁcant
decreases in the augmented responses of HR and HF,
although other parameters were little affected (Fig. 2).
Averaged data from Experiment 2 are shown in Figs. 3
and 4. Three blockers were administered i.p. in sequential
combinations: phentolamine (10 mg/kg) as an a-adreno-
ceptor antagonist of vascular sympathetic control, atenolol
(10 mg/kg) as a b1-adrenoceptor antagonist of cardiac
sympathetic control and atropine (10 mg/kg) as a musca-
rinic antagonist of cardiac parasympathetic control.
Figure 3 shows averaged data with responses of car-
diovascular parameters following phentolamine pretreat-
ment in conscious rats. Administration of phentolamine
alone signiﬁcantly decreased SBP (108.1–79.6 mmHg,
p = 0.0001) and increased HR (282.8–429.6 bpm,
p\0.0001) (Fig. 3); these results are consistent with those
observed under unanesthesia in Experiment 1 (Fig. 1b). In
terms of frequency components, phentolamine signiﬁcantly
reduced LF (p = 0.0179) and MF (p = 0.0023), and
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Fig. 1 Different effects of the anesthetized (using isoﬂurane) and
unanesthetized states on autonomic nervous function. a Effect of
atropine (10 mg/kg, i.p.) on heart rate (HR). b Effects of phentol-
amine (10 mg/kg, i.p.) on HR and systolic arterial blood pressure
(SBP). c Differences in SBP variability (SBPV; 10-min recording
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and ***p\0.001 when compared with bl (paired t test); 
p\0.05, p\0.01 and p\0.001 compared with the unanes-
thetized and anesthetized states (paired t test). PSD power spectrum
density, LF low frequency component, MF middle frequency
component, HF high frequency component. All abbreviations in
subsequent ﬁgures are the same as in this ﬁgure
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123inversely augmented HF (p\0.0001) (Fig. 3). The
increases in HR and HF were markedly suppressed by
subsequent treatment with atenolol (HR 454.7–288.8 bpm,
p\0.0001, HF 2.508–0.193 mmHg
2/Hz, p\0.0001)
(Figs. 2, 3), but not with atropine (Fig. 3). Atropine
administration after phentolamine treatment had only an
insigniﬁcant effect on all parameters.
Effects of preceding treatment with atenolol on cardio-
vascular parameters in conscious rats are indicated in
Fig. 4. Treatment with atenolol alone led to a decrease in
HR (288.5–264.8 bpm, p = 0.0181), but did not affect
SBP. In terms of frequency components, atenolol induced a
small but signiﬁcant decrease in HF (p = 0.0175), though
no change was observed in LF and MF (Fig. 4). Phentol-
amine administration after atenolol treatment decreased
SBP (111.4–83.3 mmHg, p = 0.0008) in a manner similar
to that observed when phentolamine was administered
alone (Figs. 1b, 2, 3); however, it did not change HR. As
for the frequency components, phentolamine administra-
tion after atenolol treatment decreased MF (p = 0.026) in
the same way as that observed when phentolamine was
administered alone (Figs. 1b, 2, 3), but, unlike phentol-
amine alone, it did not increase HF (Fig. 4). Augmentation
of HF after phentolamine administration occurred only
when phentolamine was administered alone, but not when
the rats were pretreated with atenolol (Figs. 3, 4), i.e., HF
was enhanced only when b-adrenoceptor was intact. In
addition, MF decreased only when phentolamine was
injected, regardless of pretreatment with other blockers
(Figs. 3, 4). Atropine administration after atenolol treat-
ment increased HR (260.8–329.5 bpm, p = 0.0029), but
the other parameters remained unchanged (Fig. 4).
Throughout this experiment, atropine had little effect on
each SBPV component, even after preceding treatment
with phentolamine or atenolol (Figs. 3, 4).
Effects of autonomic blockers on cardiovascular
parameters during exposure to low ambient temperature
(LT-exposure)
The results from Experiment 2 indicated that the changes in
MF and HF may be interrelated with administration of
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amine: after atropine administration (10 mg/kg, i.p., n = 5) following
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values) plots, and SBPV data are presented as mean ± SEM.
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***p\0.001 compared with baseline (paired t test); p\0.05, 
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123phentolamine or atenolol, respectively. In Experiment 3, we
examined the responses of cardiovascular parameters to
systemic sympathetic activation by exposure to low ambi-
ent temperature (LT-exposure) for 90 min (Fig. 5).
LT-exposure induced signiﬁcant increases in SBP (98.6–
123.8 mmHg, p\0.0001) and HR (297.6–446.7 bpm,
p\0.0001). All frequency components of SBPV were also
enhanced (LF p = 0.0023, MF p\0.0001, HF
p\0.0001) by LT-exposure (Fig. 5; see control).
Effects of the autonomic antagonists on LT-exposure
were examined. Augmentation of SBP, LF and MF during
LT-exposure was signiﬁcantly suppressed by phentolamine
administration (10 mg/kg, i.p.) before exposure (SBP
123.8–75.7 mmHg, p\0.0001, LF p = 0.0002, MF
p = 0.0001). In contrast, the increase in HR was not
reduced in the phentolamine treatment group, and HF was
more enhanced than that in the control group (p = 0.0011)
(Fig. 5; see control vs. phentolamine).
Atenolol pretreatment signiﬁcantly suppressed augmen-
tation of HR and HF during LT-exposure, and the effects
were dose dependent [HR 371.3 bpm (atenolol 1 mg/kg,
i.p.), 325.1 bpm (atenolol 10 mg/kg, i.p.), p\0.0001 in
control vs. 1 mg/kg, p = 0.009 in 1 mg/kg vs. 10 mg/kg;
HF: 0.360 mmHg
2/Hz (1 mg/kg), 0.175 mmHg
2/Hz
(10 mg/kg), p = 0.0125 in control vs. 1 mg/kg, p = 0.012
in1vs.10 mg/kg].Otherparameters,SBP,LFandMFinthe
atenolol pretreatment group were not signiﬁcantly different
from those in the control group (Fig. 5).
In summary, MF was attenuated after phentolamine
administration (a-adrenoceptor blocker), and HF was
reduced after atenolol administration (b-adrenoceptor
blocker).
Discussion
Inthisstudy,weinvestigatedHRandSBPresponsestothree
kinds of autonomic blockers under resting and systemic
sympathetic activated conditions. Involvement of sympa-
thetic cardiovascular function in SBPV frequency compo-
nents were explored pharmacologically through the effects
oftheseblockers.WefoundthateachSBPVcomponenthasa
speciﬁc correspondence with vasomotor or cardiac sympa-
thetic function, respectively, in conscious rats.
Suppression of the autonomic nervous system
by isoﬂurane anesthesia
Many studies regarding the involvement of ANS in SBPV
havebeenconductedintheanesthetizedstate[14–16]because
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treatment. HR, SBP, and SBPV data are presented as in Fig. 3. In this
ﬁgure, 20-min data were employed in the same manner as those used
in Fig. 3.* p\0.05, **p\0.01 and ***p\0.001 compared with
baseline (paired t test);p\0.05, p\0.01 and p\0.001
when compared with ﬁrst and second treatment [two-way analysis of
variance (ANOVA) and Holm’s post hoc test]
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123of the simple methods, but it may be important to examine
natural responses in the conscious state, in particular, con-
sidering sequential measurements of changes in complicated
pathological conditions such as chronic pain [18–20].
Isoﬂurane anesthesia is widely clinically used as an
inhalant anesthetic because it is well tolerated. In this
study, isoﬂurane anesthesia induced signiﬁcant changes of
baseline in HR and SBP; HR became higher and SBP
became lower than under unanesthesia (Fig. 1a, b). In
terms of frequency components of baseline data, the power
of LF and MF components of SBPV in the anesthetized
state signiﬁcantly decreased compared to those in the
unanesthetized state (Fig. 1c), thus supporting results of
other studies [23, 24]. Lower frequency components such
as LF and MF are generally considered to be attributed to
the inﬂuence of sympathetic nervous function [22, 25];
therefore, our results suggest that isoﬂurane anesthesia may
depress ANS function.
Pharmacological experiments conducted under isoﬂu-
rane anesthesia indicated that atropine acting as a musca-
rinic receptor antagonist had no effect on HR (Fig. 1a).
Given the result that HR in baseline under anesthesia was
higher (Fig. 1a, b), isoﬂurane anesthesia may induce vagal
suppression, conﬁrming the results of other studies that
reported that respiratory sinus arrhythmia [26] and HR
[26, 27] remained unchanged after surgical vagotomy in
isoﬂurane-anesthetized rats. In addition, phentolamine
administration (a-adrenoceptor antagonist) in this study
induced a decrease in SBP regardless of the induction of
anesthesia, but had no effect on HR in the anesthetized
state (Fig. 1b). These results suggest that the central ner-
vous system involved in baroreﬂex may also be depressed
by isoﬂurane anesthesia.
Relationship between MF component and a-
adrenoceptor-mediated vasomotor function
At rest, MF in this study was reduced when phentolamine
was administered as an a-adrenoceptor blocker (Figs. 2, 3,
4, 5), which is consistent with the results of other studies
[9–12]. Phentolamine-induced decreases in MF occurred
reliably, regardless of whether phentolamine was admin-
istered alone or in combination; MF was consistently
unaffected by atenolol administration (b-adrenoceptor
antagonist). The MF component of SBPV in this study may
have changed solely depending on vasomotor function
via the a-adrenoceptor, but not on cardiac sympathetic
function. In our preliminary experiment, we conﬁrmed that
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Fig. 5 Effects of autonomic blockers on cardiovascular parameters
during exposure to low ambient temperature (LT-exposure): baseline:
before LT-exposure (n = 9); control: during LT-exposure without an
autonomic blocker (n = 9); atenolol: during LT-exposure after
intraperitoneal (i.p.) injection of atenolol (1 mg/kg, n = 5o r
10 mg/kg, n = 5); phentolamine: during LT-exposure after i.p.
injection of phentolamine (10 mg/kg, n = 5). HR, SBP and SBPV
data are presented as in Fig. 3. Averaged 30-min data were used as
baseline data, and 90-min data throughout the exposure period were
used for the LT-exposure groups. *p\0.05, **p\0.01 and
***p\0.001 compared with baseline and control (paired t test); 
p\0.05, p\0.01 and p\0.001 compared among LT-expo-
sure groups [one-way analysis of variance (ANOVA) and Holm’s post
hoc test]
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123saline administration induced no signiﬁcant changes in BP,
HR and each component of SBPV (data not shown).
Therefore, we did not use saline administration in a control
group in this study.
Exposure to low ambient temperature (LT-exposure) in
our experiment induced signiﬁcant augmentation of SBP
and HR, which is indicative of systemic sympathetic acti-
vation and also conﬁrms the results of other studies [28].
MF of SBPV signiﬁcantly increased during LT-exposure;
however, phentolamine pretreatment suppressed augmen-
tation of SBP and MF (Fig. 5). These results in a systemic
sympathetic activated state also indicated a strong rela-
tionship between MF and vasomotor function.
The MF component of blood pressure variability (BPV)
has been considered to be involved in vasomotor nerve
activity via an arterial baroreﬂex in previous studies of
humans [25] and animals [8, 10, 29]. However, the detailed
characteristics of MF have remained unclear because the
method of sequential administration of different types of
autonomic antagonists at rest and in a sympathetic activated
statehasneverbeenused.Ourstudyrevealedtherelationship
between MF and a-adrenoceptor-mediated vasomotor
function using this more comprehensive method.
Relationship between HF component
and b-adrenoceptor-mediated cardiac
sympathetic function
In this study, the a-adrenoceptor blocker, which induced a
decrease in SBP, profoundly enhanced the HF component
of SBPV (Figs. 2, 3). A similar effect was observed by
other authors [9, 11, 12] and has been considered to be
attributed to the mechanical effect of respiration on intra-
thoracic pressure as blood vessels relax or dilate. Our
results, however, showed that the enhanced-HF caused by
the a-adrenoceptor blocker was markedly suppressed by
subsequent treatment with the b-adrenoceptor blocker
(Fig. 3). In addition, results with the b-adrenoceptor
blocker indicated that HF did not increase, even when SBP
was decreased by the a-adrenoceptor blocker (Fig. 4), i.e.,
once the b-adrenoceptor was blocked, either before or after
the a-adrenoceptor blocker was used, HF remained at a low
level. These ﬁndings indicate that the HF component may
be linked to b-adrenoceptor-mediated cardiac sympathetic
function rather than the mechanical effects of respiration.
HF of SBPV is in the same frequency as that of heart rate
variability (HRV), which is considered to correspond to
respiratory ﬂuctuations. The mechanism underlying the HF
respiratory component in the BP wave causes controversy as
to whether mechanical effects of respiration [9, 12, 13]o r
involvement of ANS, particularly in the cardiac sympathetic
nervous system [14–16], is involved; however, previous
studies that indicated an association between cardiac
sympathetic function and HF were performed in the anes-
thetizedstate.Inourstudyusingconsciousanimals,wefound
thatHFcomponentappearstobeinvolvedinb-adrenoceptor-
mediatedcardiacsympatheticfunctionratherthanrespiration.
An increase in the HF component of SBPV in
mechanically ventilated, anesthetized rats has been repor-
ted to be induced blood-loss-dependently by hemorrhage
[11, 16], and the HF component is considered to be an
index of blood volume status. Meanwhile, during gradation
of hemorrhage or alleviation of myocardial preload, com-
pensation via the sympathetic nervous system generally
works as a circulation system. In the light of our results,
augmentation of HF after a-adrenoceptor blockade may
reﬂect baroreceptor responses as compensatory activation
of the b-adrenoceptor-mediated sympathetic nervous sys-
tem caused by alleviation of the myocardial preload in the
same manner as that observed during hemorrhage.
Atenolol administration alone in this study induced a
small but signiﬁcant decrease in HF (Fig. 4), and atropine
administration after atenolol treatment had no effect on HF
(Fig. 4). In addition, the amplifying effect of phentolamine
on HF was reduced by subsequent treatment with atenolol
but not with atropine (Fig. 3). It has been reported that
respiratory-related arterial BPV in anesthetized rats is
attenuated by the b-adrenoceptor blocker [14–16, 21], but
not by vagotomy [14] or atropine [16]. Our results imply
that there may be a negative involvement of the vagal
function in the genesis of the HF component of SBPV.
We found that the augmented HF induced by LT-
exposure was dose-dependently suppressed by b-adrener-
gic blocker before exposure (Fig. 5). The HF component
was enhanced under alleviation of myocardial preload by
the a-adrenoceptor blockade and also under augmentation
of the preload by LT-exposure (systemic sympathetic
activation), i.e., when the cardiac sympathetic nervous
system was activated. The b-adrenergic system was indi-
cated to be involved in the genesis of HF in this study. It
may be possible that HF of SBPV is applied not only as a
speciﬁc reﬂection of a baroreﬂex compensatory response,
but also as a general marker of b-adrenergic sympathetic
excitation. In this study, we activated the cardiac sympa-
thetic nervous system indirectly (with use of phentolamine
or LT-exposure). In order to establish the method to
evaluate various pathological states, it may be necessary to
perform further experiments under several conditions, such
as using an autonomic agonist or speciﬁc animal model in
which the b-adrenergic system is enhanced.
Conclusion
In this study, we showed that the MF and HF components
of SBPV in conscious rats may reﬂect the activity of
J Physiol Sci (2011) 61:373–383 381
123vasomotor and cardiac sympathetic nervous systems,
respectively, during systemic sympathetic activation as
well as during sympathetic deactivation by autonomic
antagonists. Our results also demonstrated that isoﬂurane
anesthesia depressed ANS. We suggest that the MF and HF
components of SBPV may act as alternative means of
monitoring vasomotor and cardiac sympathetic regulation
in a conscious state. Further research is required concern-
ing the link between nerve activity and each component in
the unanesthetized states or changes in autonomic nervous
function under complicated pathological conditions.
Hopefully, such approaches will help enhance the func-
tionality of current BP monitoring and improve our
understanding of autonomic dysfunction.
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